SAFETY DATA SHEET

Montelukast Tablet Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Montelukast Tablet Formulation

Manufacturer or supplier’s details
Company name of supplier: Organon & Co.
Address: Avenida 16 de Septiembre No. 301
Xaltocan - Xochimilco Mexico 16090
Telephone: 52 55 57284444
Emergency telephone: 215-631-6999
E-mail address: EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Carcinogenicity (Inhalation): Category 2

GHS label elements
Hazard pictograms: 

Signal Word: Warning
Hazard Statements: H351 Suspected of causing cancer if inhaled.
Precautionary Statements: Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.
SAFETY DATA SHEET
Montelukast Tablet Formulation

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture
Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>&gt;= 30 - &lt; 50</td>
</tr>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>&gt;= 5 - &lt; 10</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 5</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>&gt;= 0.1 - &lt; 1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled
If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact
Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed
Suspected of causing cancer if inhaled.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders
First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media
None known.

Specific hazards during firefighting
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products
Carbon oxides
Metal oxides

Specific extinguishing methods
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters:
In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

| Personal precautions, protective equipment and emergency procedures | Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8). |
| Environmental precautions | Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained. |
| Methods and materials for containment and cleaning up | Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements. |

SECTION 7. HANDLING AND STORAGE

| Technical measures | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | Use only with adequate ventilation. |
| Advice on safe handling | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | If exposure to chemical is likely during typical use, provide eye... |
flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**Conditions for safe storage**
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

**Materials to avoid**
- Do not store with the following product types:
  - Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>VLE-PPT</td>
<td>10 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td>Montelukast</td>
<td>151767-02-1</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>VLE-PPT</td>
<td>10 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>13463-67-7</td>
<td>VLE-PPT</td>
<td>10 mg/m³</td>
<td>NOM-010-STPS-2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

**Engineering measures**
- All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
- Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
- Minimize open handling.

**Personal protective equipment**
- **Respiratory protection**
  - If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Hand protection: Chemical-resistant gloves
Remarks: Consider double gloving.
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: tablet
Color: colored
Odor: odorless
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: No data available
Relative vapor density: No data available
## SECTION 10. STABILITY AND REACTIVITY

<table>
<thead>
<tr>
<th>Property</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reactivity</td>
<td>Not classified as a reactivity hazard.</td>
</tr>
<tr>
<td>Chemical stability</td>
<td>Stable under normal conditions.</td>
</tr>
<tr>
<td>Possibility of hazardous reactions</td>
<td>May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.</td>
</tr>
<tr>
<td>Conditions to avoid</td>
<td>Heat, flames and sparks.</td>
</tr>
<tr>
<td></td>
<td>Avoid dust formation.</td>
</tr>
<tr>
<td>Incompatible materials</td>
<td>Oxidizing agents</td>
</tr>
<tr>
<td>Hazardous decomposition products</td>
<td>No hazardous decomposition products are known.</td>
</tr>
</tbody>
</table>

## SECTION 11. TOXICOLOGICAL INFORMATION

### Information on likely routes of exposure
- Inhalation
- Skin contact
- Ingestion
- Eye contact

### Acute toxicity
Not classified based on available information.

### Components:

#### Cellulose:
- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
SAFETY DATA SHEET
Montelukast Tablet Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>02.10.2020</td>
<td>23084-00017</td>
<td>23.03.2020</td>
<td>17.10.2014</td>
</tr>
</tbody>
</table>

Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

**Montelukast:**

- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
  - LD50 (Mouse): > 5,000 mg/kg
- Acute inhalation toxicity: Remarks: No data available
- Acute dermal toxicity: Remarks: No data available

**Magnesium stearate:**

- Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
  - Method: OECD Test Guideline 423
  - Assessment: The substance or mixture has no acute oral toxicity
  - Remarks: Based on data from similar materials
- Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
  - Remarks: Based on data from similar materials

**Titanium dioxide:**

- Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
- Acute inhalation toxicity: LC50 (Rat): > 6.82 mg/l
  - Exposure time: 4 h
  - Test atmosphere: dust/mist
  - Assessment: The substance or mixture has no acute inhalation toxicity

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Montelukast:**

- Species: Rabbit
- Result: Mild skin irritation

**Magnesium stearate:**

- Species: Rabbit
- Result: No skin irritation
- Remarks: Based on data from similar materials

**Titanium dioxide:**

- Species: Rabbit
Result: No skin irritation

**Serious eye damage/eye irritation**
Not classified based on available information.

**Components:**

**Montelukast:**
Species: Rabbit
Result: Severe irritation

**Magnesium stearate:**
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

**Titanium dioxide:**
Species: Rabbit
Result: No eye irritation

**Respiratory or skin sensitization**

**Skin sensitization**
Not classified based on available information.

**Respiratory sensitization**
Not classified based on available information.

**Components:**

**Montelukast:**
Remarks: No data available

**Magnesium stearate:**
Test Type: Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

**Titanium dioxide:**
Test Type: Local lymph node assay (LLNA)
Routes of exposure: Skin contact
Species: Mouse
Result: negative

**Germ cell mutagenicity**
Not classified based on available information.
Components:

Cellulose:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Montelukast:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo: Test Type: Chromosomal aberration
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Magnesium stearate:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
**SAFETY DATA SHEET**

**Montelukast Tablet Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.5</td>
<td>02.10.2020</td>
<td>23084-00017</td>
<td>23.03.2020</td>
<td>17.10.2014</td>
</tr>
</tbody>
</table>

Result: negative

Genotoxicity in vivo:
- **Test Type:** In vivo micronucleus test
- **Species:** Mouse
- **Result:** negative

**Carcinogenicity**
Suspected of causing cancer if inhaled.

**Components:**

**Cellulose:**
- **Species:** Rat
- **Application Route:** Ingestion
- **Exposure time:** 72 weeks
- **Result:** negative

**Montelukast:**
- **Species:** Rat
- **Application Route:** Oral
- **Exposure time:** 2 Years
- **Result:** negative

- **Species:** Mouse
- **Application Route:** Oral
- **Exposure time:** 92 weeks
- **Result:** negative

**Titanium dioxide:**
- **Species:** Rat
- **Application Route:** inhalation (dust/mist/fume)
- **Exposure time:** 2 Years
- **Method:** OECD Test Guideline 453
- **Result:** positive
- **Remarks:** The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment:
- Limited evidence of carcinogenicity in inhalation studies with animals.

**Reproductive toxicity**
Not classified based on available information.

**Components:**

**Cellulose:**
- **Effects on fertility:**
  - **Test Type:** One-generation reproduction toxicity study
  - **Species:** Rat
  - **Application Route:** Ingestion
  - **Result:** negative

- **Effects on fetal development:**
  - **Test Type:** Fertility/early embryonic development
  - **Species:** Rat
Montelukast:

Effects on fertility:
- Test Type: Fertility
  - Species: Rat, male
  - Application Route: Oral
  - Fertility: NOAEL: 800 mg/kg body weight
  - Result: Animal testing did not show any effects on fertility.

  Test Type: Fertility
  - Species: Rat, female
  - Application Route: Oral
  - Fertility: LOAEL: 200 mg/kg body weight
  - Symptoms: Reduced fertility

  Test Type: Fertility
  - Species: Rat, female
  - Application Route: Oral
  - Fertility: NOAEL: 100 mg/kg body weight
  - Symptoms: Reduced fertility

Magnesium stearate:

Effects on fertility:
- Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 422
  - Result: negative
  - Remarks: Based on data from similar materials

Effects on fetal development:
- Test Type: Embryo-fetal development
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
  - Remarks: Based on data from similar materials

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Cellulose:
- Species: Rat
- NOAEL: >= 9,000 mg/kg
- Application Route: Ingestion
- Exposure time: 90 Days
Montelukast:
Species: Monkey, male and female
NOAEL: 150 - 300 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 53 Weeks
Remarks: No significant adverse effects were reported

Species: Mouse
NOAEL: 50 mg/kg
Application Route: Oral
Exposure time: 14 Weeks
Remarks: No significant adverse effects were reported

Magnesium stearate:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials

Titanium dioxide:
Species: Rat
NOAEL: 24,000 mg/kg
Application Route: Ingestion
Exposure time: 28 Days

Species: Rat
NOAEL: 10 mg/m³
Application Route: inhalation (dust/mist/fume)
Exposure time: 2 y

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
Montelukast:
Skin contact: Remarks: May irritate skin.
Eye contact: Symptoms: Severe irritation
Ingestion: Symptoms: upper respiratory tract infection, pharyngitis, Headache, Cough, Abdominal pain, Diarrhea, Fever
ECOTOXICITY

Components:

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Montelukast:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility.

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.23 mg/l
Exposure time: 21 d
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:
EC50: > 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209
Remarks: No toxicity at the limit of solubility.
Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
   Exposure time: 48 h
   Method: DIN 38412
   Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
   Exposure time: 47 h
   Test substance: Water Accommodated Fraction
   Remarks: Based on data from similar materials
   No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
   Exposure time: 72 h
   Test substance: Water Accommodated Fraction
   Method: OECD Test Guideline 201
   Remarks: Based on data from similar materials
   No toxicity at the limit of solubility.

Titanium dioxide:
Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
   Exposure time: 96 h
   Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 100 mg/l
   Exposure time: 48 h

Toxicity to algae/aquatic plants:

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
   Exposure time: 16 h
   Test substance: Water Accommodated Fraction
   Remarks: Based on data from similar materials

Persistence and degradability

Components:
Cellulose:
Biodegradability: Result: Readily biodegradable.
Montelukast Tablet Formulation

Montelukast:
Biodegradability: Result: not rapidly degradable
Biodegradation: 0 %
Exposure time: 28 d
Stability in water: Hydrolysis: 50 % (21.7 h)

Magnesium stearate:
Biodegradability: Result: Not biodegradable.
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:
Montelukast:
Partition coefficient: n-octanol/water: log Pow: > 4.3

Magnesium stearate:
Partition coefficient: n-octanol/water: log Pow: > 4

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
SAFETY DATA SHEET
Montelukast Tablet Formulation

Version 4.5  Revision Date: 02.10.2020  SDS Number: 23084-00017  Date of last issue: 23.03.2020
Date of first issue: 17.10.2014

NOM-002-SCT
Not regulated as a dangerous good

Special precautions for user
Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. Not applicable

The ingredients of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
NOM-010-STPS-2014: Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits
ACGIH / TWA: 8-hour, time-weighted average
NOM-010-STPS-2014 / VLE-PPT: Time weighted average limit value

AICIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECl - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New
SAFETY DATA SHEET
Montelukast Tablet Formulation

Version 4.5  Revision Date: 02.10.2020  SDS Number: 23084-00017  Date of last issue: 23.03.2020  Date of first issue: 17.10.2014

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - Quantitative Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System


Revision Date: 02.10.2020

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8